Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:24
  • preuzimanja u poslednjih 30 dana:6

Sadržaj

članak: 1 od 10  
Back povratak na rezultate
2020, vol. 37, br. 2, str. 99-120
Nodalne i ekstranodalne periferne T/NK ćelijske neoplazme - savremeni aspekti
aUniverzitet u Nišu, Medicinski fakultet, Departman za onkologiju, Niš + Klinički centar Niš, Klinika za onkologiju
bKlinički centar Niš, Klinika za onkologiju

e-adresaivan.petkovic@medfak.ni.ac.rs
Ključne reči: T/NK ćelijski limfomi; nodalni; ekstranodalni; tretman; novi agensi
Sažetak
Periferni T/NK ćelijski limfomi (PTCL) su retki i izrazito heterogeni maligni tumori. Bolest je sklona relapsima, sa visokom stopom hemiorefraktarnosti, što vodi ka lošem ukupnom ishodu lečenja. Kod gotovo 70% bolesnika dolazi do relapsa, dok se petogodišnja stopa preživljavanja kreće oko 30%. Uvodna linija lečenja PTCL je interpolirana od principa lečenja agresivnih B ćelijskih NHL. Univerzalno prihvaćena, prva linija lečenja prevashodno je palijativna. Pored maksimalnih napora da se poboljša primarni pristup, samo je period do progresije bolesti produžen, dok efekta na ukupno preživljavanje nema. Svi aktuelni vodiči ističu važnost autologne transplantacije matičnih ćelija hematopoeze (Auto-SCT), kao konsolidacije prvog povoljnog terapijskog odgovora. Primena alogene transplantacije (Allo-SCT) u prvoj remisiji i dalje nije potkrepljena medicinom baziranom na dokazima, te je s toga njena upotreba indikovana kod relaps/refraktornih PTCL. Nažalost, većina bolesnika nisu kandidati za agresivne tretmane, te je preporučeni pristup ograničeno primenjiv. Imajući u vidu trenutnu situaciju, neophodni su novi terapijski agensi. Postojeći rezultati ukazuju na ukupnu lošu prognozu bolesti, međutim uvođenjem L-asparaginaze, kao i target terapije kod CD30+ entiteta, došlo je do značajnog poboljšanja lečenja pojedinih PTCL. Značajan broj novih agenasa uključen je u rane faze kliničkih istraživanja, sa ohrabrujućim rezultatima. Pažnja je usmerena na rezultate tih studija, imajući u vidu da trenutno nema adekvatnih tretmana za bolesnike koji su relapsirali ili su refraktarni na primenjene terapije.
Reference
Abramson, J.S., Feldman, T., Kroll-Desrosiers, A.R., Muffly, L.S., Winer, E., Flowers, C.R., Lansigan, F., Nabhan, C., Nastoupil, L.J., Nath, R., Goy, A., Castillo, J.J., Jagadeesh, D., Woda, B., Rosen, S.T., Smith, S.M., Evens, A.M. (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy. Annals of Oncology, 25(11): 2211-2217
Advani, R.H., Ansell, S.M., Lechowicz, M.J., Beaven, A.W., Loberiza, F., Carson, K.R., Evens, A.M., Foss, F., Horwitz, S., Pro, B., Pinter-Brown, L.C., Smith, S.M., Shustov, A.R., Savage, K.J. (2016) A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial. British Journal of Haematology, 172(4): 535-544
Amengual, J.E., Lichtenstein, R., Rojas, C., et al. (2016) The pralatrexate-romidepsin doublet: A well tolerated and highly effective combination for patients with relapsed or refractory peripheral T-cell lymphoma. Blood, 128: 1824A
Asano, N., Suzuki, R., Kagami, Y., Ishida, F., Kitamura, K., Fukutani, H., Morishima, Y., Takeuchi, K., Nakamura, S. (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. American Journal of Surgical Pathology, 29(10): 1284-1293
Attygalle, A.D., Kyriakou, C., Dupuis, J., Grogg, K.L., Diss, T.C., Wotherspoon, A.C., Chuang, S.S., Cabeçadas, J., Isaacson, P.G., du Ming-Qing,, Gaulard, P., Dogan, A. (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: Clinical correlation and insights into natural history and disease progression. American Journal of Surgical Pathology, 31(7): 1077-1088
Avila, M., Aquilar, H., Demichelis, G.R., et al. (2018) Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: A single Mexican center experience. Blood Res, 53(3): 210-227
Barr, P.M., Li, H., Spier, C., Mahadevan, D., Leblanc, M., Ul, H.M., Huber, B.D., Flowers, C.R., Wagner-Johnston, N.D., Horwitz, S.M., Fisher, R.I., Cheson, B.D., Smith, S.M., Kahl, B.S. (2015) Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. Journal of Clinical Oncology, 33(21): 2399-2404
Bayle, C., Charpentier, A., Duchayne, E., Manel, A., Pages, M., Robert, A., Lamant, L., Dastugue, N., Bertrand, Y., Dijoud, F., Emile, J., Machover, D., Brugieres, L., Delsol, G. (1999) Leukaemic presentation of small cell variant anaplastic large cell lymphoma: Report of four cases. British Journal of Haematology, 104(4): 680-688
Biggar, R.J., Engels, E.A., Frisch, M., Goedert, J.J. (2000) Risk of T-cell lymphomas in persons with AIDS. Journal of Acquired Immune Deficiency Syndromes, 26(4): 371-376
Bu, S., Yuan, F., Wei, X., Yin, Q., Li, Y., Mi, R., Yang, H., Li, H., Ge, S., Liu, Y., Song, Y. (2016) L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma. Experimental and Therapeutic Medicine, 11(6): 2437-2445
Carson, K.R., Horwitz, S.M., Pinter-Brown, L.C., Rosen, S.T., Pro, B., Hsi, E.D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L.A., Acosta, M.A., Shustov, A.R., Advani, R.H., Feldman, T.A. (2017) A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer, 123(7): 1174-1183
Castellar, E.R.P., Jaffe, E.S., Said, J.W., et al. (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 124(9): 1473-80
Chan, J.K., Tsang, W.Y., Ng, C.S. (1996) Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: The neoplastic cells are often CD3 epsilon. Blood, 87(2): 839-841
Clemens, M.W., Brody, G.S., Mahabir, R.C., Miranda, R.N. (2018) How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plastic and Reconstructive Surgery, 141(4): 586e-599e
Corradini, P., Dodero, A., Zallio, F., Caracciolo, D., Casini, M., Bregni, M., Narni, F., Patriarca, F., Boccadoro, M., Benedetti, F., Rambaldi, A., Gianni, A.M., Tarella, C. (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 22(11): 2172-2176
Cuadros, M., Dave, S.S., Jaffe, E.S., Honrado, E., Milne, R., Alves, J., Rodríguez, J., Zajac, M., Benitez, J., Staudt, L.M., Martinez-Delgado, B. (2007) Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. Journal of Clinical Oncology, 25(22): 3321-3329
Damaj, G., Gressin, R., Bouabdallah, K., Cartron, G., Choufi, B., Gyan, E., Banos, A., Jaccard, A., Park, S., Tournilhac, O., Schiano, de C.J., Voillat, L., Joly, B., Le, G.S., Saad, A. (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial. Journal of Clinical Oncology, 31(1): 104-110
d'Amore F., Gaulard, P., Trümper, L., Corradini, P., Kim, W.-S., Specht, L., Bjerregaard, P.M., Ladetto, M. (2015) Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(suppl 26): v108-v115
d'Amore Francesco,, Relander, T., Lauritzsen, G.F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., Kuittinen, O., Erlanson, M., Østenstad, B., Fagerli, U., Gadeberg, O.V. (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of Clinical Oncology, 30(25): 3093-3099
de Jong, D., Vasmel, W.L., de Boer, J.P., et al. (2008) Anaplastic large-cell lymphoma in women with breast implants. JAMA, 300(17): 2030-2035
de Leval, L., Gaulard, P. (2008) Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program, 2008(1): 272-279
de Leval, L., Rickman, D.S., Thielen, C., de Reynies, A., Huang, Y., Delsol, G., Lamant, L., Leroy, K., Brière, J., Molina, T., Berger, F., Gisselbrecht, C., Xerri, L., Gaulard, P. (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood, 109(11): 4952-4963
Delarue, R., Dupuis, J., Sujobert, P., Barbieux, S., Marçais, A., Tournilhac, O., Lachenal, F., Cheminant, M., Sarkozy, C., Fataccioli, V., Morschhauser, F., Hermine, O., Haioun, C., Gaulard, P. (2016) Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas. Blood, 128(22): 4164A
Dupuis, J., Emile, J.-F., Mounier, N., Gisselbrecht, C., Martin-Garcia, N., Petrella, T., Bouabdallah, R., Berger, F., Delmer, A., Coiffier, B., Reyes, F., Gaulard, P. (2006) Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood, 108(13): 4163-4169
Dupuis, J., Boye, K., Martin, N., et al. (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol, 30(4): 490-494
Ellin, F., Landström, J., Jerkeman, M., Relander, T. (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. Blood, 124(10): 1570-1577
Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., Macdonald, A.P., Repp, R., Schetelig, J., Seipelt, G., Österborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103(8): 2920-2924
Fanale, M.A., Hagemeister, F.B., Fayad, L., Oki, Y., Fowler, N., Romaguera, J., Shah, N., Chuang, H., Feng, L., Horowitz, S.B., Wesson, E., Hutto, T.Y., Muzzafar, T., Samaniego, F., Davis, R. E. (2014) A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B and T-cell lymphomas. Blood, 124(21): 1744A
Felgar, R.E., Macon, W.R., Kinney, M.C., et al. (1997) TIA-1 expression in lymphoid neoplasms: Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol, 150 (6): 1893-900
Ferreri, A.J.M., Govi, S., Pileri, S.A. (2012) Hepatosplenic gamma-delta T-cell lymphoma. Critical Reviews in Oncology/Hematology, 83(2): 283-292
Feyler, S., Prince, H.M., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D.I., Cook, G. (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplantation, 40(5): 443-450
Friedberg, J.W., Mahadevan, D., Cebula, E., Persky, D., Lossos, I., Agarwal, A.B., Jung, J., Burack, R., Zhou, X., Leonard, E. J., Fingert, H., Danaee, H., Bernstein, S.H. (2014) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive band T-cell non-Hodgkin lymphomas. Journal of Clinical Oncology, 32(1): 44-50
Gambacorti, P.C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., Mussolin, L., Deeren, D., King, M.H., Steurer, M., Ordemann, R. (2014) Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. JNCI: Journal of the National Cancer Institute, 106(2): djt378
Gaulard, P., de Leval, L. (2014) Pathology of peripheral T-cell lymphomas: Where do we stand?. Seminars in Hematology, 51(1): 5-16
Gentille, C., Qin, Q., Barbieri, A., Sai, R.P., Iyer, S. (2017) Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience, 11: 771-771
Grogg, K.L., Morice, W.G., Macon, W.R. (2007) Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. British Journal of Haematology, 137(5): 416-422
Hari, P., Raj, R.V., Olteanu, H. (2016) Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. New England Journal of Medicine, 375(15): 1501-1502
Holkova, B., Yazbeck, V., Kmieciak, M., Bose, P., Ma, S., Kimball, A., Tombes, M.B., Shrader, E., Wan, W., Weir-Wiggins, C., Singh, A., Hogan, K.T., Conine, S., Sankala, H., Roberts, J.D., Shea, T.C., Grant, S. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma, 58(6): 1349-1357
Horwitz, S., O'Connor, O.A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Lennard, A. (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet, 393(10168): 229-240
Horwitz, S.M., Ansell, S.M., Ai, W.Z., Barnes, J., Barta, S.K., Choi, M., Clemens, M.W., Dogan, A., Greer, J.P., Halwani, A., Haverkos, B.M., Hoppe, R.T., Jacobsen, E., Jagadeesh, D., Kim, Y.H. (2018) NCCN guidelines insights: T-cell lymphomas: Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(2): 123-135
Horwitz, S.M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J.D., Morrow, S.N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V. (2018) Activity of the PI3K-d,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood, 131(8): 888-898
Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R.D., Weisenburger, D.D., Greiner, T.C., Smith, L., Guo, S., Wilcox, R.A., Teh, B.T., Lim, S.T., Tan, S.Y., Rimsza, L.M., Jaffe, E.S. (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 123(19): 2915-2923
Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., Mckeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W.Y. (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood, 115(5): 1026-1036
Islam, S., Vick, E., Huber, B., Morales, C., Spier, C., Cooke, L., Weterings, E., Mahadevan, D. (2017) Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: A novel therapeutic strategy. Oncotarget, 8(59): 100326-100338
Jaccard, A., Gachard, N., Marin, B., Rogez, S., Audrain, M., Suarez, F., Tilly, H., Morschhauser, F., Thieblemont, C., Ysebaert, L., Devidas, A., Petit, B., de Leval, L., Gaulard, P., Feuillard, J. (2011) Efficacy of L-asparaginase with methotrexate and Dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma: A phase 2 study. Blood, 117(6): 1834-1839
Jantunen, E., Boumendil, A., Finel, H., Luan, J., Johnson, P., Rambaldi, A., Haynes, A., Duchosal, M.A., Bethge, W., Biron, P., Carlson, K., Craddock, C., Rudin, C., Finke, J., Salles, G. (2013) Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT. Blood, 121(13): 2529-2532
Kanakry, J.A., Kasamon, Y.L., Gocke, C.D., Tsai, H., Davis-Sproul, J., Ghosh, N., Symons, H., Bolaños-Meade, J., Gladstone, D.E., Swinnen, L.J., Luznik, L., Fuchs, E.J., Jones, R.J. (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biology of Blood and Marrow Transplantation, 19(4): 602-606
Kim, B., Roth, C., Young, V. L., Chung, K.C., van Busum, K., Schnyer, C., Mattke, S. (2011) Anaplastic large cell lymphoma and breast implants. Plastic and Reconstructive Surgery, 128(3): 629-639
Kim, H.K., Moon, S.M., Moon, J.H., Park, J.E., Byeon, S., Kim, W.S. (2015) Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Research, 50(4): 254-256
Kim, S.J., Yoon, D.H., Kang, H.J., Kim, J.S., Park, S.K., Kim, H.J., Lee, J., Ryoo, B., Ko, Y.H., Huh, J., Yang, W.I., Kim, H.K., Min, S.K., Lee, S., Do, I., Suh, C., Kim, W.S. (2012) Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. European Journal of Cancer, 48(17): 3223-3231
Kim, W.S., Song, S.-Y., Ahn, Y.C., Ko, Y.-H., Baek, C.-H., Kim, D.Y., Yoon, S.-S., Lee, H.G., Kang, W.K., Lee, H.J., Park, C.R., Park, K. (2001) CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Annals of Oncology, 12(3): 349-352
Kinney, M.C., Collins, R.D., Greer, J.P., Whitlock, J.A., Sioutos, N., Kadin, M.E. (1993) A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. American Journal of Surgical Pathology, 17(9): 859-868
Kwong, Y., Kim, W.S., Lim, S.T., Kim, S.J., Tang, T., Tse, E., Leung, A.Y.H., Chim, C. (2012) SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 120(15): 2973-2980
Kwong, Y., Chan, T.S.Y., Tan, D., Kim, S.J., Poon, L., Mow, B., Khong, P., Loong, F., Au-Yeung, R., Iqbal, J., Phipps, C., Tse, E. (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood, 129(17): 2437-2442
Kyriakou, C., Canals, C., Finke, J., Kobbe, G., Harousseau, J., Kolb, H., Novitzky, N., Goldstone, A.H., Sureda, A., Schmitz, N. (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 27(24): 3951-3958
Lanier, L.L., Testi, R., Bindl, J., Phillips, J.H. (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. Journal of Experimental Medicine, 169(6): 2233-2238
Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., Millenson, M.M., Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M., Avigan, D., Chapuy, B., Ligon, A.H. (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. Journal of Clinical Oncology, 34(23): 2698-2704
Li, L., Duan, W., Zhang, L., Li, X., Fu, X., Wang, X., Wu, J., Sun, Z., Zhang, X., Chang, Y., Nan, F., Yan, J., Li, Z., Young, K.H., Zhang, M. (2017) The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. British Journal of Haematology, 178(5): 772-780
Loch-Wilkinson, A., Beath, K.J., Knight, R.J.W., Wessels, W.L.F., Magnusson, M., Papadopoulos, T., Connell, T., Lofts, J., Locke, M., Hopper, I., Cooter, R., Vickery, K., Joshi, P.A. (2017) Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand. Plastic and Reconstructive Surgery, 140(4): 645-654
Maeda, Y., Nishimori, H., Yoshida, I., Hiramatsu, Y., Uno, M., Masaki, Y., Sunami, K., Masunari, T., Nawa, Y., Yamane, H., Gomyo, H., Takahashi, T., Yano, T., Matsuo, K., Ohshima, K. (2017) Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: A multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 102(12): 2097-2103
Mahadevan, D., Unger, J.M., Spier, C.M., Persky, D.O., Young, F., Leblanc, M., Fisher, R.I., Miller, T.P. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group study S0350. Cancer, 119(2): 371-379
Makita, S., Maeshima, A.M., Maruyama, D., Izutsu, K., Tobinai, K. (2018) Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: An evidence-based review. OncoTargets and Therapy, Volume 11: 2287-2293
Malamut, G., Chandesris, O., Verkarre, V., Meresse, B., Callens, C., Macintyre, E., Bouhnik, Y., Gornet, J., Allez, M., Jian, R., Berger, A., Châtellier, G., Brousse, N., Hermine, O. (2013) Enteropathy associated T cell lymphoma in celiac disease: A large retrospective study. Digestive and Liver Disease, 45(5): 377-384
Mehta-Shah, N., Lunning, M.A., Boruchov, A.M., et al. (2015) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. J Clin Oncol, 33 (suppl 15): 8521A
Mehta-Shah, N., Moskowitz, A.J., Lunning, M., Lynch, P., Scheuerman, M., Kumar, A., Gerecitano, J.F., Zelenetz, A.D., Hamlin, P.A., Noy, A., Matasar, M.J., Palomba, M. L., Younes, A., Schaffer, W., Grewal, R. (2016) A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. Blood, 128(22): 2991A
Moskowitz, A.J., Koch, R., Mehta-Shah, N., et al. (2017) In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-inhibitor in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma. Blood, 130 (suppl 1): 819A
Nijeboer, P., de Baaij, L.R., Visser, O., Witte, B.I., Cillessen, S.A.G.M., Mulder, C.J., Bouma, G. (2015) Treatment response in enteropathy associated T-cell lymphoma: Survival in a large multicenter cohort. American Journal of Hematology, 90(6): 493-498
O'Connor, O.A., Falchi, L., Lue, J.K., et al. (2019) Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase I study. Blood, e pub ahead of print
O'Connor, O.A., Horwitz, S., Masszi, T., van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M.R., Walewski, J., Savage, K., Foss, F., Allen, L.F. (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. Journal of Clinical Oncology, 33(23): 2492-2499
O'Connor, O.A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo, L.M., Savage, K.J., Shustov, A.R., Gisselbrecht, C., Jacobsen, E., Zinzani, P.L., Furman, R., Goy, A. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. Journal of Clinical Oncology, 29(9): 1182-1189
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., Tanimoto, M., Tsukasaki, K., Ishizawa, K., Suzumiya, J. (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Journal of Clinical Oncology, 32(11): 1157-1163
Oki, Y., Haverkos, B., Zain, J.M., Lechowicz, M.J., Devata, S., Korman, N.J., Ramchandren, R., Pinter-Brown, L.C., Barde, P.J., Nair, A., Huen, A. (2018) Tenalisib, a dual PI3K d/g inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. Journal of Clinical Oncology, 36(15_suppl): 7510-7510, ASCOAbstract
Park, S., Ko, Y.H. (2014) Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders. Journal of Dermatology, 41(1): 29-39
Perry, A.M., Warnke, R.A., Hu, Q., Gaulard, P., Copie-Bergman, C., Alkan, S., Wang, H., Cheng, J.X., Bacon, C.M., Delabie, J., Ranheim, E., Kucuk, C., Hu, X., Weisenburger, D.D., Jaffe, E.S. (2013) Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood, 122(22): 3599-3606
Petković, I. (2015) Current trends in the treatment of primary mediastinal large B-cell lymphoma: An overview. Współczesna Onkologia / Contemp Oncol, Poznan, 19(6): 428-435
Petrella, T., Maubec, E., Cornillet-Lefebvre, P., et al. (2007) Indolent CD8-positive lymphoid proliferation of the ear: A distinct primary cutaneous T-cell lymphoma. Am J Surg Pathol, 31(12): 1887-92
Poon, L., Kwong, Y. (2016) Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Annals of Hematology, 95(5): 847-849
Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J.M., Yang, Y., Sievers, E.L., Kennedy, D.A., Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of Clinical Oncology, 30(18): 2190-2196
Qi, W., Spier, C., Liu, X., Agarwal, A., Cooke, L.S., Persky, D.O., Chen, D., Miller, T.P., Mahadevan, D. (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia Research, 37(4): 434-439
Quintanilla-Martinez, L. (2017) The 2016 updated WHO classification of lymphoid neoplasias. Hematological Oncology, 35(S1): 37-45
Rodríguez-Pinilla, S.M., Atienza, L., Murillo, C., Pérez-Rodríguez, A., Montes-Moreno, S., Roncador, G., Pérez-Seoane, C., Domínguez, P., Camacho, F.I., Piris, M.A. (2008) Peripheral T-cell lymphoma with follicular T-cell markers. American Journal of Surgical Pathology, 32(12): 1787-1799
Sakata-Yanagimoto, M., Enami, T., Yoshida, K., et al. (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet, 46 (2): 171-5
Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., Chhanabhai, M., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D. (2008) ALK-negative anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood, 111(12): 5496-5504
Schmitz, N., Trümper, L., Ziepert, M., Nickelsen, M., Ho, A.D., Metzner, B., Peter, N., Loeffler, M., Rosenwald, A., Pfreundschuh, M. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group S0350. Blood, 116(18): 3418-3425
Schmitz, N., de Leval, L. (2017) How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: Current practice and a glimpse into the future. British Journal of Haematology, 176(6): 851-866
Shustov, A., Coiffier, B., Horwitz, S., Sokol, L., Pro, B., Wolfson, J., Balser, B., Eisch, R., Popplewell, L., Prince, H. M., Allen, S.L., Piekarz, R., Bates, S. (2017) Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: Analysis of two phase II trials. Leukemia & Lymphoma, 58(10): 2335-2341
Sun, J.C., Lanier, L.L. (2011) NK cell development, homeostasis and function: Parallels with CD8+ T cells. Nature Reviews Immunology, 11(10): 645-657
Swerdlow, S.H., Jaffe, E.S., Brousset, P., et al., International Lymphoma Study Group (2014) Cytotoxic T-cell and NK-cell lymphomas: Current questions and controversies. Am J Surg Pathol, 38(10): e60-e71
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2008) WHO classification of tumours of haemotopoietic and lymphoid tissues. Geneva: World Health Organization
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D., Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20): 2375-2390
Tan, S.-Y., Ooi, A.-S., Ang, M.-K., Koh, M., Wong, J.-C., Dykema, K., Ngeow, J., Loong, S., Gatter, K., Tan, L.Y., Lim, L.-C., Furge, K., Tao, M., Lim, S.-T., Loong, F., Cheah, P.L., Teh, B.-T. (2011) Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia, 25(3): 555-557
Thanarajasingam, G., Edell, E.S., Markovic, S.M. (2016) Complete response of anaplastic lymphoma kinase-mutated refractory extranodal natural killer/T-cell lymphoma to crizotinib. Mayo Clinic Proceedings, 91(9): 1319-1320
Vose, J., Armitage, J., Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. Journal of Clinical Oncology, 26(25): 4124-4130
Voss, M.H., Lunning, M.A., Maragulia, J.C., Papadopoulos, E.B., Goldberg, J., Zelenetz, A.D., Horwitz, S.M. (2013) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience. Clinical Lymphoma Myeloma and Leukemia, 13(1): 8-14
Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P.P., Ascani, S., Sabattini, E., Bacci, F., Falini, B., Motta, T., Paulli, M., Artusi, T., Piccioli, M., Zinzani, P.L., Pileri, S.A. (2006) Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. Journal of Clinical Oncology, 24(16): 2472-2479
Witzig, T., Sokol, L., Jacobsen, E., Advani, R., Mondejar, R., Piris, M., Burrows, F., Melvin, C., Mishra, V., Scholz, C., Gualberto, A. (2017) Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. Hematological Oncology, 35(S2): 251-252
Yamaguchi, M., Oguchi, M., Suzuki, R. (2018) Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Practice & Research Clinical Haematology, 31(3): 315-321
Yamaguchi, M., Tobinai, K., Oguchi, M., Ishizuka, N., Kobayashi, Y., Isobe, Y., Ishizawa, K., Maseki, N., Itoh, K., Usui, N., Wasada, I., Kinoshita, T., Hotta, T., Tsukasaki, K., Oshimi, K. (2012) Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: An updated analysis of the Japan Clinical Oncology Group study JCOG0211. Journal of Clinical Oncology, 30(32): 4044-4046
Yang, L., Liu, H., Xu, X., Wang, X., Huang, H., Shi, W., Jiang, S. (2013) Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Medical Oncology, 30(4): 720-720
Zinzani, P.L., Magagnoli, M., Bendandi, M., Orcioni, G. F., Gherlinzoni, F., Albertini, P., Pileri, S.A., Tura, S. (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology, 9(12): 1351-1353
Zinzani, P.L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S., Baccarani, M. (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome. Annals of Oncology, 21(4): 860-863
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/afmnai37-24708
objavljen u SCIndeksu: 06.08.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka